DelMar Pharmaceuticals Announces Presentations at Upcoming Scientific Meetings
VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 6, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, today announced that the company has been invited to present new advancements at two upcoming peer reviewed scientific meetings.
AACR New Horizons in Cancer Research 2014: October 9-12, 2014, Shanghai
DelMar has been invited to present an abstract to support the activity of VAL-083 in the treatment of non-small cell lung cancer (NSCLC).
Society for NeuroOncology (SNO) Annual Meeting: November 13-16, 2014, Miami
DelMar has been invited to present multiple abstracts regarding the development of VAL-083 as a potential new treatment for glioblastoma multiforme (GBM).
Details of the company's scientific presentations will be available on the company's website: http://www.delmarpharma.com/products/publications/
About DelMar Pharmaceuticals
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
SOURCE DelMar Pharmaceuticals
Released October 6, 2014